ALIS (Amikacin Liposome Inhalation Suspension)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ALIS (Amikacin Liposome Inhalation Suspension), covering 2026-02-03 to 2026-02-03. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex [Phase 3]